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Table S1. Protocol Inclusion/Exclusion Criteria. 
Eligible subjects must: 
• Be able to understand and comply with protocol requirements, instructions, and 
restrictions; 
• Be likely to complete the study as planned; 
• Be considered appropriate candidates for participation in an investigative clinical trial 
with oral medication (e.g., no active substance abuse, acute major organ disease). 
Subjects eligible for enrollment in this study must meet all of the following: 
1. HIV-1 infected adults ≥18 years of age.  
2. A female, may be eligible to enter and participate in the study if she: 
a. Is of non-child-bearing potential defined as either post-menopausal (12 months of 
spontaneous amenorrhea and ≥45 years of age) or physically incapable of becoming 
pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy, or 
b. Is of child-bearing potential with a negative pregnancy test at both Screening and Day 1 
and agrees to use one of the following methods of contraception to avoid pregnancy: 
• Complete abstinence from intercourse from 2 weeks prior to administration of 
investigational product (IP), throughout the study, and for at least 2 weeks after 
discontinuation of all study medications. 




• Any intrauterine device (IUD) with published data showing that the expected failure 
rate is <1% per year (not all IUDs meet this criterion; see the study procedure manual 
for an example listing of approved IUDs). 
• Any other method with published data showing that the expected failure rate is <1% 
per year. 
• Hormonal contraception plus a barrier method. Hormonal contraception alone will not 
be considered adequate for inclusion into or participation in this study (due to 
potential receipt of blinded efavirenz in this trial). 
3. HIV-1 infection as documented by Screening plasma HIV-1 RNA ≥1000 copies/mL. 
4. Antiretroviral-naive (≤10 days of prior therapy with any antiretroviral agent following a 
diagnosis of HIV-1 infection). 
5. A negative HLA-B*5701 allele screening assessment. 
6. Signed and dated written informed consent is obtained from the subject or the subject’s 
legal representative prior to screening. 
7. For subjects enrolled in France: a subject will be eligible for inclusion in this study only if 
either affiliated with or a beneficiary of a social security category. 
Exclusionary Medical Conditions 
1. Women who are breastfeeding. 
2. Any evidence of an active Center for Disease Control and Prevention (CDC) Category C 
disease, except cutaneous Kaposi’s sarcoma not requiring systemic therapy. Historical or 
current CD4 cell counts <200 cells/mm3 are not exclusionary. 
3. Subjects with any degree of hepatic impairment. 
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4. Positive for Hepatitis B at screening (+HbsAg), or anticipated need for Hepatitis C virus 
therapy during the study. 
5. Recent history (≤3 months) of any upper or lower gastrointestinal bleed, with the exception 
of anal or rectal bleeding. 
6. History or presence of allergy or intolerance to the study drugs, their components, or drugs 
of their class. 
7. History of malignancy within the past 5 years or ongoing malignancy other than cutaneous 
Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell 
carcinoma; other localized malignancies require agreement between the investigator and 
Study medical monitor for inclusion of the subject. 
Exclusionary Treatments prior to Screening or Day 1 
8. Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening. 
9. Treatment with any of the following agents within 28 days of Screening: 
i. Radiation therapy 
ii. Cytotoxic chemotherapeutic agents 
iii. Any immunomodulator 
10. Treatment with any agent, except recognized antiretroviral therapy as allowed above, with 
documented activity against HIV-1 in vitro within 28 days of first dose of IP. Allowed 
antiretroviral therapy cannot be given within 28 days of first dose. 
11. Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives 
of the test agent, or twice the duration of the biological effect of the test agent, whichever is 
longer, prior to the first dose of IP. 
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12. French subjects recruited at sites in France will be excluded if the subject has participated in 
any study using an investigational agent during the previous 60 days or 5 half-lives, or twice 
the duration of the biological effect of the experimental drug or vaccine, whichever is longer, 
prior to screening for the study or if the subject will participate simultaneously in another 
clinical study. 
Exclusionary Laboratory or Clinical Assessments at Screening  
13. Any evidence of primary viral resistance in the Screening result or, if known, any historical 
resistance test result; Note: retests of Screening genotypes are not allowed. 
14. Any verified Grade 4 laboratory abnormality (a single repeat test is allowed during the 
Screening period); any acute laboratory abnormality at Screening, which, in the opinion of 
the Investigator, would preclude the subject’s participation in the study of an investigational 
compound is exclusionary. 
15. Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN). 
16. ALT ≥3xULN and bilirubin ≥1.5xULN (with >35% direct bilirubin). 














The study statistician generated the randomization schedule with 
GlaxoSmithKline-validated randomization software RANDALL.  
Care providers enrolled participants and used an automated phone system 
to retrieve container numbers from the randomization system as well as a 
randomization number from the randomization schedule. 
Blinding The sponsor central study team (including CG, KP, BW, SM, and GN) 
remained blinded until the last subject’s week 48 visit for the primary 
analysis. Participants, sponsor study site staff, and care providers will 
remain blinded until each subject’s week 96 visit. The sponsor clinical trial 
supplies group was unblinded in order to package and label the clinical 
trials supplies. The care providers may unblind a subject’s treatment 
assignment only in the case of an emergency. The sponsor global clinical 
safety and pharmacovigilance group was partially unblinded, as required by 
various country regulations, in order to process reports of serious, related, 




Subjects’ responses (<50 copies/mL) were calculated according to the US 
Food and Drug Administration’s Snapshot algorithm. It is intended to be 
primarily a virologic assessment of the endpoint, and as such follows a 
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(Snapshot) “virology first” hierarchy. 
Virologic success (<50 copies/mL) or virologic failure is typically determined 
by the last available HIV-1 RNA measurement within the visit window of 
interest (48 weeks ± 6 weeks) while the subject is on treatment. 
When no HIV-1 RNA data are available within a window, a subject is 
considered a non-responder. Depending on the reason for the lack of data, 
the subject will be classified as a virologic failure or reported as “no 
virologic data at week 48”; in the latter case, the algorithm further classifies 
the nature of the missing data. Typically, a subject withdrawn (1) due to AE 
or, (2) for another reason yet was suppressed at the time, will be counted 
as “no virologic data at week 48.” Should a subject withdraw for reasons 
other than adverse events and were not suppressed at the time, they would 
be classified a virologic failure. 
A subject may also be considered a virologic failure if they make changes 
to their background regimen. Since changes in antiretroviral therapy are not 
permitted in this protocol, all such subjects who change antiretroviral 
therapy are considered non-responders.  




All subgroup analyses (for stratification factors and other subject 
characteristics) were pre-specified and unadjusted for multiplicity. 
Stratification factors: 
For the statistical analysis of the primary endpoint, 4 subgroups were 
formed according to the combinations of levels of the stratification factors: 
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Baseline plasma HIV-1 RNA (≤ vs. >100,000 c/mL) and baseline CD4 cell 
count (≤ vs. >200 cells/mm3). For these strata, in addition to the proportion 
of responders by treatment arm and subgroup (with 95% CI), the P value 
from the test of homogeneity was also reported for each categorical 
variable. Tests of homogeneity were assessed at the 1-sided 10% level of 
significance. These results were used to assess the statistical assumption 
underlying the Cochran Mantel Haenszel stratified analysis procedure—
namely the assumption on a common difference in unadjusted proportions 
across strata. 
Other subject characteristics: 
A simple analysis of the primary endpoint for all the subgroups listed below 
was performed. This showed the proportion of responders by treatment and 
subgroup, and a 95% CI for the (unadjusted) treatment difference in each 
subgroup. These analyses were exploratory and likely underpowered so 
that interpretation may therefore focus on point estimates as well as the 
lower bounds of 95% CIs for the treatment differences and response rates. 
Additionally, multiple comparisons were being made, which inflates the risk 
of false-positive findings. Therefore, if consistent findings across the 
multiple comparisons were observed, then these analyses would still be 
suggestive of a generalizable finding of non-inferiority. For brevity, only 
baseline HIV-1 RNA (≤100,000 or >100,000 copies/mL), baseline CD4 cell 
count (≤200 or >200 cells/mm3), gender, race (white or non-white), and age 
(<50 or ≥50 years) are presented in this manuscript. 
• Baseline plasma HIV-1 RNA: 
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a. ≤100,000 or >100,000 copies/mL; 
b. <1000; 1000 to <10,000; 10,000 to <50,000; 50,000 to 
100,000; >100,000 copies/mL. 
• Baseline CD4 cell count: 
a. ≤200 or >200 cells/mm3; 
b. <50; 50 to <200; 200 to <350; 350 to <500; ≥500 cells/mm3. 
• Baseline CDC category (CDC Category A, CDC Category B, or 
CDC Category C) 
• Race (white or non-white) and race 2 (African American/African 
heritage or non–African American/African heritage) 
• Gender (female or male) 
• Age: 
a. <36 or ≥36 years (i.e., baseline median cutoff); 
b. <65 or ≥65 years; 
c.  <50 or ≥50 years; this post hoc category was added after 
review of the data, as the number of subjects in the ≥65 years 
category (n=1 in the DTG+ABC/3TC arm and n=6 in the Atripla arm) 
planned in the protocol to look at response in the elderly population 
was too small for any meaningful interpretation. 
• Country 
• Known HIV risk factors or mode of transmission (injectable drug 
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user, homosexual contact and not injectable drug user, or no 
homosexual contact and not injectable drug user) 
CDC denotes Centers for Disease Control and Prevention, CI confidence interval. 
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Table S3. Summary of Protocol Deviations Leading to Exclusion From the Per-Protocol 
Population (ITT-E Population) Through Week 48. 
Protocol deviations* 











Any deviation 11 (3) 7 (2) 18 (2) 
Inclusion/exclusion criteria 1 (<1) 1 (<1) 2 (<1) 
Subject took/received incorrect 
study drug >10% of total 
treatment time 
1 (<1) 0 1 (<1) 
Study drug interruption for >10% of 
total treatment time 
2 (<1) 1 (<1) 3 (<1) 
Use of prohibited medication† 2 (<1) 3 (<1) 5 (<1) 
Permanent discontinuation of study 
drug due to protocol deviation 
6 (1) 4 (<1) 10 (1) 
*Some subjects may have multiple deviations leading to exclusion from the per-protocol 
population; deviations may appear in more than one category. †Prohibited medications included 
prednisone, methylprednisolone, methotrexate, and infliximab. ABC denotes abacavir, CI 
confidence interval, DTG dolutegravir, EFV efavirenz, FTC emtricitabine, ITT-E denotes 




Table S4. Summary of Demographic Characteristics (ITT-E Population). 
 











Age in years, median (range) 36.0 (18-68) 35.0 (18-85) 35.0 (18-85) 
Sex    
Male 347 (84) 356 (85) 703 (84) 
Female 67 (16) 63 (15) 130 (16) 
Ethnicity    
Hispanic/Latino 56 (14) 56 (13) 112 (13) 
Not Hispanic/Latino 358 (86) 363 (87) 721 (87) 
Race    
African American/African heritage 98 (24) 99 (24) 197 (24) 
American Indian or Alaska native 13 (3) 17 (4) 30 (4) 
Asian 9 (2) 9 (2) 18 (2) 
Central/South Asian heritage 2 (<1) 3 (<1) 5 (<1) 
Japanese/East Asian heritage/ 
Southeast Asian heritage 
7 (2) 6 (1) 13 (2) 
Native Hawaiian or other Pacific Islander 0 0 0 
White – White/Caucasian/European 
heritage 
284 (69) 285 (68) 569 (68) 















Baseline HIV-1 RNA (log10 copies/mL)    
≤100,000 280 (68) 288 (69) 568 (68) 
>100,000 134 (32) 131 (31) 265 (32) 
Median 4.67 4.70 4.68 
Baseline CD4 (cells/mm3)    
<50 13 (3) 14 (3) 27 (3) 
50 to <200 44 (11) 48 (11) 92 (11) 
200 to <350 163 (39) 159 (38) 322 (39) 
350 to <500 131 (32) 128 (31) 259 (31) 
≥500 63 (15) 70 (17) 133 (16) 
Median 334.5 339.0 338.0 
Hepatitis C positive* 27 (7) 29 (7) 56 (7) 
CDC category    
A: Asymptomatic or lymphadenopathy or 
acute HIV 
343 (83) 350 (84) 693 (83) 
B: Symptomatic, not AIDS 53 (13) 52 (12) 105 (13) 
C: AIDS 18 (4) 17 (4) 35 (4) 
HIV risk factors known    















Homosexual contact 268 (67) 289 (71) 557 (69) 
Heterosexual contact 133 (33) 111 (27) 244 (30) 
Injectable drug use 20 (5) 9 (2) 29 (4) 
Transfusion 2 (<1) 1 (<1) 3 (<1) 
Hemophilia-associated injections 0 2 (<1) 2 (<1) 
Occupational exposure 0 0 0 
Vertical/Perinatal transmission 0 1 (<1) 1 (<1) 
Other 5 (1) 12 (3) 17 (2) 
*Hepatitis C status was determined using antibody (IgM or IgG) and/or hepatitis C virus RNA 
assessments performed during screening or during the conduct of the study. If both antibody 
and virus RNA assessments were available, then the latter took precedence and 
positive/negative status was based on whether hepatitis C virus RNA was detectable. ABC 
denotes abacavir, CI confidence interval, DTG dolutegravir, EFV efavirenz, FTC emtricitabine, 






Table S5. Summary of All Adverse Events by System Organ Class and Maximum Toxicity. 
Protocol: ING114467  
Population: Safety  
Summary of All Adverse Events by System Organ Class and Maximum Toxicity 
 
Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 




39 (9%) 4 (<1%) 369 
(89%) 
       
Infections and infestations      
Any Event 131 
(32%) 
88 (21%) 13 (3%) 0 232 
(56%) 
Nasopharyngitis 57 (14%) 5 (1%) 0 0 62 (15%) 
Upper respiratory tract infection 27 (7%) 9 (2%) 0 0 36 (9%) 
Bronchitis 12 (3%) 6 (1%) 2 (<1%) 0 20 (5%) 
Gastroenteritis 12 (3%) 3 (<1%) 0 0 15 (4%) 
Sinusitis 10 (2%) 4 (<1%) 1 (<1%) 0 15 (4%) 
Influenza 8 (2%) 6 (1%) 0 0 14 (3%) 
Syphilis 6 (1%) 6 (1%) 1 (<1%) 0 13 (3%) 
Pharyngitis 5 (1%) 4 (<1%) 0 0 9 (2%) 
Pneumonia 2 (<1%) 6 (1%) 1 (<1%) 0 9 (2%) 
Tonsillitis 5 (1%) 3 (<1%) 0 0 8 (2%) 
Cellulitis 2 (<1%) 5 (1%) 0 0 7 (2%) 
Folliculitis 6 (1%) 1 (<1%) 0 0 7 (2%) 
Urethritis 4 (<1%) 3 (<1%) 0 0 7 (2%) 
Gonorrhoea 4 (<1%) 2 (<1%) 0 0 6 (1%) 
Tooth abscess 1 (<1%) 5 (1%) 0 0 6 (1%) 
Urinary tract infection 4 (<1%) 2 (<1%) 0 0 6 (1%) 
Chlamydial infection 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Otitis media 1 (<1%) 4 (<1%) 0 0 5 (1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Respiratory tract infection 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Tinea pedis 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Oral herpes 4 (<1%) 0 0 0 4 (<1%) 
Rhinitis 4 (<1%) 0 0 0 4 (<1%) 
Abscess 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Acarodermatitis 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Acute sinusitis 0 3 (<1%) 0 0 3 (<1%) 
Herpes simplex 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Otitis externa 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Subcutaneous abscess 1 (<1%) 1 (<1%) 1 (<1%) 0 3 (<1%) 
Tinea cruris 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Acute tonsillitis 2 (<1%) 0 0 0 2 (<1%) 
Body tinea 2 (<1%) 0 0 0 2 (<1%) 
Ear infection 2 (<1%) 0 0 0 2 (<1%) 
Furuncle 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Genital herpes 2 (<1%) 0 0 0 2 (<1%) 
Giardiasis 2 (<1%) 0 0 0 2 (<1%) 
Gingival infection 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Herpes virus infection 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Herpes zoster 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Infectious mononucleosis 2 (<1%) 0 0 0 2 (<1%) 
Molluscum contagiosum 2 (<1%) 0 0 0 2 (<1%) 
Orchitis 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Pharyngitis streptococcal 0 2 (<1%) 0 0 2 (<1%) 
Pharyngotonsillitis 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Tinea versicolour 2 (<1%) 0 0 0 2 (<1%) 
Vaginitis bacterial 2 (<1%) 0 0 0 2 (<1%) 
Viral upper respiratory tract infection 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Wound infection 2 (<1%) 0 0 0 2 (<1%) 
Abscess limb 0 1 (<1%) 0 0 1 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Anal chlamydia infection 1 (<1%) 0 0 0 1 (<1%) 
Anorectal infection 0 1 (<1%) 0 0 1 (<1%) 
Appendicitis 0 0 1 (<1%) 0 1 (<1%) 
Balanitis candida 1 (<1%) 0 0 0 1 (<1%) 
Blastocystis infection 0 1 (<1%) 0 0 1 (<1%) 
Conjunctivitis infective 1 (<1%) 0 0 0 1 (<1%) 
Cryptosporidiosis infection 0 1 (<1%) 0 0 1 (<1%) 
Cystitis 0 0 1 (<1%) 0 1 (<1%) 
Enterobiasis 1 (<1%) 0 0 0 1 (<1%) 
Eye infection 1 (<1%) 0 0 0 1 (<1%) 
Fungal skin infection 0 1 (<1%) 0 0 1 (<1%) 
Genital candidiasis 1 (<1%) 0 0 0 1 (<1%) 
Genitourinary chlamydia infection 1 (<1%) 0 0 0 1 (<1%) 
Helicobacter gastritis 0 1 (<1%) 0 0 1 (<1%) 
Infected dermal cyst 0 0 1 (<1%) 0 1 (<1%) 
Laryngitis 0 1 (<1%) 0 0 1 (<1%) 
Latent tuberculosis 1 (<1%) 0 0 0 1 (<1%) 
Localised infection 1 (<1%) 0 0 0 1 (<1%) 
Lower respiratory tract infection 0 1 (<1%) 0 0 1 (<1%) 
Lung infection 1 (<1%) 0 0 0 1 (<1%) 
Lymphogranuloma venereum 1 (<1%) 0 0 0 1 (<1%) 
Meningitis 0 1 (<1%) 0 0 1 (<1%) 
Mycobacterium avium complex infection 0 1 (<1%) 0 0 1 (<1%) 
Neurosyphilis 0 0 1 (<1%) 0 1 (<1%) 
Onychomycosis 1 (<1%) 0 0 0 1 (<1%) 
Oral infection 1 (<1%) 0 0 0 1 (<1%) 
Oropharyngeal gonococcal infection 1 (<1%) 0 0 0 1 (<1%) 
Papilloma viral infection 0 0 1 (<1%) 0 1 (<1%) 
Parasitic gastroenteritis 0 1 (<1%) 0 0 1 (<1%) 
Parotitis 1 (<1%) 0 0 0 1 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Pharyngitis bacterial 0 1 (<1%) 0 0 1 (<1%) 
Post procedural cellulitis 0 1 (<1%) 0 0 1 (<1%) 
Post procedural infection 0 0 1 (<1%) 0 1 (<1%) 
Postoperative wound infection 0 0 1 (<1%) 0 1 (<1%) 
Proctitis gonococcal 1 (<1%) 0 0 0 1 (<1%) 
Pyelonephritis 0 0 1 (<1%) 0 1 (<1%) 
Sialoadenitis 0 1 (<1%) 0 0 1 (<1%) 
Skin infection 0 1 (<1%) 0 0 1 (<1%) 
Staphylococcal abscess 0 1 (<1%) 0 0 1 (<1%) 
Staphylococcal infection 0 1 (<1%) 0 0 1 (<1%) 
Staphylococcal skin infection 1 (<1%) 0 0 0 1 (<1%) 
Tinea infection 0 1 (<1%) 0 0 1 (<1%) 
Toxoplasmosis 0 1 (<1%) 0 0 1 (<1%) 
Tracheitis 1 (<1%) 0 0 0 1 (<1%) 
Tracheobronchitis 0 1 (<1%) 0 0 1 (<1%) 
Tuberculosis 0 0 1 (<1%) 0 1 (<1%) 
Viral infection 1 (<1%) 0 0 0 1 (<1%) 
Vulval abscess 1 (<1%) 0 0 0 1 (<1%) 
Vulvovaginal candidiasis 1 (<1%) 0 0 0 1 (<1%) 
Vulvovaginal mycotic infection 0 1 (<1%) 0 0 1 (<1%) 
       
Gastrointestinal disorders      
Any Event 133 
(32%) 
43 (10%) 4 (<1%) 0 180 
(43%) 
Diarrhoea 51 (12%) 20 (5%) 1 (<1%) 0 72 (17%) 
Nausea 52 (13%) 7 (2%) 0 0 59 (14%) 
Vomiting 16 (4%) 4 (<1%) 0 0 20 (5%) 
Abdominal pain upper 11 (3%) 2 (<1%) 0 0 13 (3%) 
Abdominal pain 10 (2%) 2 (<1%) 0 0 12 (3%) 
Constipation 10 (2%) 2 (<1%) 0 0 12 (3%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Flatulence 8 (2%) 4 (<1%) 0 0 12 (3%) 
Abdominal distension 10 (2%) 1 (<1%) 0 0 11 (3%) 
Dyspepsia 9 (2%) 1 (<1%) 0 0 10 (2%) 
Gastrooesophageal reflux disease 6 (1%) 3 (<1%) 1 (<1%) 0 10 (2%) 
Haemorrhoids 7 (2%) 1 (<1%) 0 0 8 (2%) 
Toothache 6 (1%) 1 (<1%) 1 (<1%) 0 8 (2%) 
Abdominal discomfort 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Gastritis 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Anogenital dysplasia 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Food poisoning 2 (<1%) 1 (<1%) 1 (<1%) 0 4 (<1%) 
Gingivitis 2 (<1%) 2 (<1%) 0 0 4 (<1%) 
Enteritis 3 (<1%) 0 0 0 3 (<1%) 
Gastric disorder 3 (<1%) 0 0 0 3 (<1%) 
Gingival bleeding 3 (<1%) 0 0 0 3 (<1%) 
Anal fissure 2 (<1%) 0 0 0 2 (<1%) 
Anorectal disorder 2 (<1%) 0 0 0 2 (<1%) 
Dental caries 2 (<1%) 0 0 0 2 (<1%) 
Frequent bowel movements 2 (<1%) 0 0 0 2 (<1%) 
Haematochezia 2 (<1%) 0 0 0 2 (<1%) 
Inguinal hernia 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Mouth ulceration 2 (<1%) 0 0 0 2 (<1%) 
Odynophagia 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Paraesthesia oral 2 (<1%) 0 0 0 2 (<1%) 
Anal ulcer 0 1 (<1%) 0 0 1 (<1%) 
Aphthous stomatitis 1 (<1%) 0 0 0 1 (<1%) 
Cheilitis 0 1 (<1%) 0 0 1 (<1%) 
Diarrhoea haemorrhagic 0 1 (<1%) 0 0 1 (<1%) 
Dry mouth 1 (<1%) 0 0 0 1 (<1%) 
Duodenitis 1 (<1%) 0 0 0 1 (<1%) 
Dysphagia 1 (<1%) 0 0 0 1 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Eructation 1 (<1%) 0 0 0 1 (<1%) 
Faecal incontinence 0 1 (<1%) 0 0 1 (<1%) 
Faeces discoloured 1 (<1%) 0 0 0 1 (<1%) 
Gastrointestinal disorder 1 (<1%) 0 0 0 1 (<1%) 
Hiatus hernia 1 (<1%) 0 0 0 1 (<1%) 
Lip dry 1 (<1%) 0 0 0 1 (<1%) 
Mallory-Weiss syndrome 0 1 (<1%) 0 0 1 (<1%) 
Oral disorder 1 (<1%) 0 0 0 1 (<1%) 
Perianal erythema 1 (<1%) 0 0 0 1 (<1%) 
Proctalgia 0 1 (<1%) 0 0 1 (<1%) 
Proctitis 0 1 (<1%) 0 0 1 (<1%) 
Rectal discharge 1 (<1%) 0 0 0 1 (<1%) 
Rectal haemorrhage 1 (<1%) 0 0 0 1 (<1%) 
Rectal prolapse 1 (<1%) 0 0 0 1 (<1%) 
Sensitivity of teeth 1 (<1%) 0 0 0 1 (<1%) 
Tongue coated 1 (<1%) 0 0 0 1 (<1%) 
Tongue disorder 1 (<1%) 0 0 0 1 (<1%) 
Tooth disorder 1 (<1%) 0 0 0 1 (<1%) 
       
Nervous system disorders      
Any Event 82 (20%) 28 (7%) 1 (<1%) 0 111 
(27%) 
Headache 43 (10%) 11 (3%) 1 (<1%) 0 55 (13%) 
Dizziness 35 (8%) 2 (<1%) 0 0 37 (9%) 
Paraesthesia 9 (2%) 1 (<1%) 0 0 10 (2%) 
Somnolence 6 (1%) 3 (<1%) 0 0 9 (2%) 
Memory impairment 1 (<1%) 3 (<1%) 0 0 4 (<1%) 
Disturbance in attention 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Dysgeusia 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Hypoaesthesia 3 (<1%) 0 0 0 3 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Lethargy 3 (<1%) 0 0 0 3 (<1%) 
Sinus headache 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Syncope 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Carpal tunnel syndrome 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Migraine 2 (<1%) 0 0 0 2 (<1%) 
Poor quality sleep 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
VIIth nerve paralysis 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Amnesia 1 (<1%) 0 0 0 1 (<1%) 
Aphonia 1 (<1%) 0 0 0 1 (<1%) 
Cerebrovascular accident 0 1 (<1%) 0 0 1 (<1%) 
Depressed level of consciousness 0 1 (<1%) 0 0 1 (<1%) 
Dysaesthesia 0 1 (<1%) 0 0 1 (<1%) 
Formication 1 (<1%) 0 0 0 1 (<1%) 
Grand mal convulsion 0 1 (<1%) 0 0 1 (<1%) 
Meralgia paraesthetica 1 (<1%) 0 0 0 1 (<1%) 
Myoclonus 1 (<1%) 0 0 0 1 (<1%) 
Neuralgia 1 (<1%) 0 0 0 1 (<1%) 
Neuropathy peripheral 0 1 (<1%) 0 0 1 (<1%) 
Post herpetic neuralgia 1 (<1%) 0 0 0 1 (<1%) 
Sleep paralysis 1 (<1%) 0 0 0 1 (<1%) 
Trigeminal neuralgia 0 1 (<1%) 0 0 1 (<1%) 
       
Psychiatric disorders      
Any Event 86 (21%) 33 (8%) 4 (<1%) 2 (<1%) 125 
(30%) 
Insomnia 47 (11%) 14 (3%) 3 (<1%) 0 64 (15%) 
Abnormal dreams 28 (7%) 2 (<1%) 0 0 30 (7%) 
Depression 16 (4%) 5 (1%) 2 (<1%) 0 23 (6%) 
Anxiety 5 (1%) 9 (2%) 0 0 14 (3%) 
Nightmare 8 (2%) 1 (<1%) 0 0 9 (2%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Libido decreased 5 (1%) 1 (<1%) 0 0 6 (1%) 
Sleep disorder 5 (1%) 1 (<1%) 0 0 6 (1%) 
Depressed mood 3 (<1%) 0 0 0 3 (<1%) 
Initial insomnia 3 (<1%) 0 0 0 3 (<1%) 
Nervousness 2 (<1%) 0 0 0 2 (<1%) 
Suicide attempt 1 (<1%) 0 0 1 (<1%) 2 (<1%) 
Adjustment disorder 1 (<1%) 0 0 0 1 (<1%) 
Adjustment disorder with depressed mood 0 1 (<1%) 0 0 1 (<1%) 
Agitation 1 (<1%) 0 0 0 1 (<1%) 
Anger 0 1 (<1%) 0 0 1 (<1%) 
Antisocial personality disorder 1 (<1%) 0 0 0 1 (<1%) 
Anxiety disorder 1 (<1%) 0 0 0 1 (<1%) 
Binge eating 1 (<1%) 0 0 0 1 (<1%) 
Bipolar disorder 0 1 (<1%) 0 0 1 (<1%) 
Depressive symptom 1 (<1%) 0 0 0 1 (<1%) 
Dysthymic disorder 0 1 (<1%) 0 0 1 (<1%) 
Euphoric mood 1 (<1%) 0 0 0 1 (<1%) 
Homicidal ideation 0 0 0 1 (<1%) 1 (<1%) 
Libido increased 1 (<1%) 0 0 0 1 (<1%) 
Mood swings 0 1 (<1%) 0 0 1 (<1%) 
Panic attack 1 (<1%) 0 0 0 1 (<1%) 
Premature ejaculation 1 (<1%) 0 0 0 1 (<1%) 
Restlessness 0 1 (<1%) 0 0 1 (<1%) 
Social phobia 0 1 (<1%) 0 0 1 (<1%) 
Substance abuse 0 1 (<1%) 0 0 1 (<1%) 
Suicidal ideation 0 0 0 1 (<1%) 1 (<1%) 
Withdrawal syndrome 1 (<1%) 0 0 0 1 (<1%) 
       
Skin and subcutaneous tissue disorders      
Any Event 70 (17%) 13 (3%) 1 (<1%) 0 84 (20%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Rash 11 (3%) 3 (<1%) 0 0 14 (3%) 
Pruritus 13 (3%) 0 0 0 13 (3%) 
Night sweats 8 (2%) 3 (<1%) 0 0 11 (3%) 
Alopecia 8 (2%) 1 (<1%) 0 0 9 (2%) 
Acne 7 (2%) 1 (<1%) 0 0 8 (2%) 
Eczema 5 (1%) 1 (<1%) 0 0 6 (1%) 
Dry skin 4 (<1%) 0 0 0 4 (<1%) 
Hyperhidrosis 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Rash pruritic 3 (<1%) 0 0 0 3 (<1%) 
Dermatitis 2 (<1%) 0 0 0 2 (<1%) 
Increased tendency to bruise 2 (<1%) 0 0 0 2 (<1%) 
Rash maculo-papular 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Rash papular 2 (<1%) 0 0 0 2 (<1%) 
Seborrhoeic dermatitis 2 (<1%) 0 0 0 2 (<1%) 
Skin irritation 2 (<1%) 0 0 0 2 (<1%) 
Angioedema 0 0 1 (<1%) 0 1 (<1%) 
Chloasma 1 (<1%) 0 0 0 1 (<1%) 
Dermatitis contact 0 1 (<1%) 0 0 1 (<1%) 
Dyshidrosis 1 (<1%) 0 0 0 1 (<1%) 
Eosinophilic pustular folliculitis 1 (<1%) 0 0 0 1 (<1%) 
Erythema 1 (<1%) 0 0 0 1 (<1%) 
Erythema nodosum 1 (<1%) 0 0 0 1 (<1%) 
Hidradenitis 0 1 (<1%) 0 0 1 (<1%) 
Hyperkeratosis 1 (<1%) 0 0 0 1 (<1%) 
Pigmentation disorder 1 (<1%) 0 0 0 1 (<1%) 
Pityriasis rosea 1 (<1%) 0 0 0 1 (<1%) 
Psoriasis 1 (<1%) 0 0 0 1 (<1%) 
Purpura 1 (<1%) 0 0 0 1 (<1%) 
Rash macular 1 (<1%) 0 0 0 1 (<1%) 
Seborrhoea 1 (<1%) 0 0 0 1 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Skin disorder 1 (<1%) 0 0 0 1 (<1%) 
Skin lesion 1 (<1%) 0 0 0 1 (<1%) 
Solar dermatitis 1 (<1%) 0 0 0 1 (<1%) 
Spider naevus 1 (<1%) 0 0 0 1 (<1%) 
Swelling face 0 1 (<1%) 0 0 1 (<1%) 
       
General disorders and administration site 
conditions 
     
Any Event 85 (21%) 15 (4%) 8 (2%) 0 108 
(26%) 
Fatigue 44 (11%) 8 (2%) 2 (<1%) 0 54 (13%) 
Pyrexia 18 (4%) 2 (<1%) 3 (<1%) 0 23 (6%) 
Asthenia 11 (3%) 1 (<1%) 0 0 12 (3%) 
Chest pain 8 (2%) 1 (<1%) 1 (<1%) 0 10 (2%) 
Chills 6 (1%) 0 0 0 6 (1%) 
Influenza like illness 5 (1%) 1 (<1%) 0 0 6 (1%) 
Oedema peripheral 5 (1%) 1 (<1%) 0 0 6 (1%) 
Pain 6 (1%) 0 0 0 6 (1%) 
Feeling hot 3 (<1%) 0 0 0 3 (<1%) 
Cyst 2 (<1%) 0 0 0 2 (<1%) 
Facial pain 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Adverse drug reaction 0 0 1 (<1%) 0 1 (<1%) 
Axillary pain 1 (<1%) 0 0 0 1 (<1%) 
Discomfort 1 (<1%) 0 0 0 1 (<1%) 
Feeling drunk 1 (<1%) 0 0 0 1 (<1%) 
Irritability 1 (<1%) 0 0 0 1 (<1%) 
Malaise 1 (<1%) 0 0 0 1 (<1%) 
Non-cardiac chest pain 0 0 1 (<1%) 0 1 (<1%) 
Papillitis 1 (<1%) 0 0 0 1 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Musculoskeletal and connective tissue 
disorders 
     
Any Event 56 (14%) 26 (6%) 2 (<1%) 0 84 (20%) 
Back pain 13 (3%) 10 (2%) 0 0 23 (6%) 
Arthralgia 10 (2%) 2 (<1%) 1 (<1%) 0 13 (3%) 
Pain in extremity 9 (2%) 4 (<1%) 0 0 13 (3%) 
Muscle spasms 8 (2%) 2 (<1%) 0 0 10 (2%) 
Myalgia 3 (<1%) 3 (<1%) 0 0 6 (1%) 
Musculoskeletal pain 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Neck pain 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Bone pain 3 (<1%) 0 0 0 3 (<1%) 
Musculoskeletal chest pain 3 (<1%) 0 0 0 3 (<1%) 
Flank pain 1 (<1%) 0 1 (<1%) 0 2 (<1%) 
Joint swelling 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Musculoskeletal stiffness 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Osteoarthritis 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Rotator cuff syndrome 2 (<1%) 0 0 0 2 (<1%) 
Tendon disorder 0 2 (<1%) 0 0 2 (<1%) 
Tendonitis 2 (<1%) 0 0 0 2 (<1%) 
Bursitis 0 1 (<1%) 0 0 1 (<1%) 
Costochondritis 0 1 (<1%) 0 0 1 (<1%) 
Fasciitis 1 (<1%) 0 0 0 1 (<1%) 
Foot deformity 1 (<1%) 0 0 0 1 (<1%) 
Groin pain 0 1 (<1%) 0 0 1 (<1%) 
Muscle fatigue 1 (<1%) 0 0 0 1 (<1%) 
Osteopenia 1 (<1%) 0 0 0 1 (<1%) 
Plantar fasciitis 1 (<1%) 0 0 0 1 (<1%) 
Sjogren's syndrome 1 (<1%) 0 0 0 1 (<1%) 
Synovial cyst 1 (<1%) 0 0 0 1 (<1%) 
Temporomandibular joint syndrome 1 (<1%) 0 0 0 1 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Tenosynovitis 0 1 (<1%) 0 0 1 (<1%) 
       
Respiratory, thoracic and mediastinal 
disorders 
     
Any Event 63 (15%) 15 (4%) 2 (<1%) 0 80 (19%) 
Cough 22 (5%) 2 (<1%) 0 0 24 (6%) 
Oropharyngeal pain 16 (4%) 4 (<1%) 0 0 20 (5%) 
Nasal congestion 8 (2%) 0 0 0 8 (2%) 
Rhinorrhoea 7 (2%) 0 0 0 7 (2%) 
Sinus congestion 7 (2%) 0 0 0 7 (2%) 
Rhinitis allergic 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Asthma 1 (<1%) 3 (<1%) 0 0 4 (<1%) 
Dyspnoea 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Epistaxis 3 (<1%) 0 0 0 3 (<1%) 
Productive cough 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Respiratory tract congestion 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Wheezing 3 (<1%) 0 0 0 3 (<1%) 
Hiccups 2 (<1%) 0 0 0 2 (<1%) 
Rhinitis seasonal 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Throat irritation 2 (<1%) 0 0 0 2 (<1%) 
Allergic sinusitis 1 (<1%) 0 0 0 1 (<1%) 
Apnoea 1 (<1%) 0 0 0 1 (<1%) 
Chronic obstructive pulmonary disease 0 1 (<1%) 0 0 1 (<1%) 
Dry throat 1 (<1%) 0 0 0 1 (<1%) 
Dysphonia 1 (<1%) 0 0 0 1 (<1%) 
Nasal ulcer 1 (<1%) 0 0 0 1 (<1%) 
Paranasal sinus hypersecretion 1 (<1%) 0 0 0 1 (<1%) 
Pleural effusion 0 0 1 (<1%) 0 1 (<1%) 
Pulmonary congestion 1 (<1%) 0 0 0 1 (<1%) 
Sneezing 1 (<1%) 0 0 0 1 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Tonsillar disorder 0 0 1 (<1%) 0 1 (<1%) 
Tonsillar hypertrophy 1 (<1%) 0 0 0 1 (<1%) 
Upper-airway cough syndrome 1 (<1%) 0 0 0 1 (<1%) 
       
Injury, poisoning and procedural 
complications 
     
Any Event 26 (6%) 14 (3%) 5 (1%) 2 (<1%) 47 (11%) 
Arthropod bite 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Muscle strain 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Procedural pain 2 (<1%) 3 (<1%) 0 0 5 (1%) 
Laceration 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Ligament sprain 2 (<1%) 2 (<1%) 0 0 4 (<1%) 
Foot fracture 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Road traffic accident 1 (<1%) 0 2 (<1%) 0 3 (<1%) 
Exposure to communicable disease 2 (<1%) 0 0 0 2 (<1%) 
Intentional overdose 0 1 (<1%) 0 1 (<1%) 2 (<1%) 
Lip injury 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Skeletal injury 2 (<1%) 0 0 0 2 (<1%) 
Tooth fracture 2 (<1%) 0 0 0 2 (<1%) 
Animal scratch 1 (<1%) 0 0 0 1 (<1%) 
Comminuted fracture 0 0 1 (<1%) 0 1 (<1%) 
Contusion 0 1 (<1%) 0 0 1 (<1%) 
Epicondylitis 1 (<1%) 0 0 0 1 (<1%) 
Head injury 0 0 1 (<1%) 0 1 (<1%) 
Heat stroke 1 (<1%) 0 0 0 1 (<1%) 
Humerus fracture 0 1 (<1%) 0 0 1 (<1%) 
Injury 1 (<1%) 0 0 0 1 (<1%) 
Jaw fracture 0 0 1 (<1%) 0 1 (<1%) 
Overdose 0 0 1 (<1%) 0 1 (<1%) 
Splinter 1 (<1%) 0 0 0 1 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Subdural haematoma 0 0 0 1 (<1%) 1 (<1%) 
Suture rupture 1 (<1%) 0 0 0 1 (<1%) 
Traumatic haematoma 0 1 (<1%) 0 0 1 (<1%) 
       
Metabolism and nutrition disorders      
Any Event 13 (3%) 5 (1%) 4 (<1%) 0 22 (5%) 
Decreased appetite 7 (2%) 0 0 0 7 (2%) 
Vitamin D deficiency 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Hypercholesterolaemia 1 (<1%) 0 1 (<1%) 0 2 (<1%) 
Hypertriglyceridaemia 0 0 2 (<1%) 0 2 (<1%) 
Cow's milk intolerance 1 (<1%) 0 0 0 1 (<1%) 
Dehydration 0 1 (<1%) 0 0 1 (<1%) 
Diabetes mellitus 1 (<1%) 0 0 0 1 (<1%) 
Dyslipidaemia 0 1 (<1%) 0 0 1 (<1%) 
Gout 0 1 (<1%) 0 0 1 (<1%) 
Hyperglycaemia 0 0 1 (<1%) 0 1 (<1%) 
Lactose intolerance 1 (<1%) 0 0 0 1 (<1%) 
Type 2 diabetes mellitus 0 1 (<1%) 0 0 1 (<1%) 
       
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
     
Any Event 16 (4%) 8 (2%) 0 0 24 (6%) 
Anogenital warts 9 (2%) 5 (1%) 0 0 14 (3%) 
Skin papilloma 5 (1%) 2 (<1%) 0 0 7 (2%) 
Lipoma 2 (<1%) 0 0 0 2 (<1%) 
Basal cell carcinoma 0 1 (<1%) 0 0 1 (<1%) 
Degeneration of uterine leiomyoma 1 (<1%) 0 0 0 1 (<1%) 
Dysplastic naevus 1 (<1%) 0 0 0 1 (<1%) 
       
Reproductive system and breast disorders      
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Any Event 18 (4%) 7 (2%) 1 (<1%) 1 (<1%) 27 (7%) 
Erectile dysfunction 4 (<1%) 2 (<1%) 0 0 6 (1%) 
Balanitis 2 (<1%) 0 0 0 2 (<1%) 
Benign prostatic hyperplasia 2 (<1%) 0 0 0 2 (<1%) 
Balanoposthitis 1 (<1%) 0 0 0 1 (<1%) 
Bartholin's cyst 0 1 (<1%) 0 0 1 (<1%) 
Breast induration 1 (<1%) 0 0 0 1 (<1%) 
Breast mass 1 (<1%) 0 0 0 1 (<1%) 
Breast tenderness 1 (<1%) 0 0 0 1 (<1%) 
Cervix disorder 0 1 (<1%) 0 0 1 (<1%) 
Dysmenorrhoea 1 (<1%) 0 0 0 1 (<1%) 
Erection increased 1 (<1%) 0 0 0 1 (<1%) 
Genital lesion 0 1 (<1%) 0 0 1 (<1%) 
Gynaecomastia 1 (<1%) 0 0 0 1 (<1%) 
Menometrorrhagia 0 1 (<1%) 0 0 1 (<1%) 
Menorrhagia 1 (<1%) 0 0 0 1 (<1%) 
Penile discharge 0 1 (<1%) 0 0 1 (<1%) 
Priapism 0 0 0 1 (<1%) 1 (<1%) 
Sexual dysfunction 1 (<1%) 0 0 0 1 (<1%) 
Uterine prolapse 0 1 (<1%) 0 0 1 (<1%) 
Vaginal discharge 0 1 (<1%) 0 0 1 (<1%) 
Vaginal haemorrhage 1 (<1%) 0 0 0 1 (<1%) 
Vulvovaginal swelling 0 0 1 (<1%) 0 1 (<1%) 
       
Investigations      
Any Event 10 (2%) 10 (2%) 2 (<1%) 0 22 (5%) 
Weight increased 5 (1%) 1 (<1%) 0 0 6 (1%) 
Blood pressure increased 1 (<1%) 3 (<1%) 0 0 4 (<1%) 
Blood creatine phosphokinase increased 0 2 (<1%) 0 0 2 (<1%) 
Hepatic enzyme increased 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Blood creatinine increased 0 1 (<1%) 0 0 1 (<1%) 
Blood glucose increased 0 1 (<1%) 0 0 1 (<1%) 
Blood testosterone decreased 1 (<1%) 0 0 0 1 (<1%) 
Blood triglycerides increased 0 1 (<1%) 0 0 1 (<1%) 
Lipase increased 0 0 1 (<1%) 0 1 (<1%) 
Liver palpable subcostal 1 (<1%) 0 0 0 1 (<1%) 
Mycobacterium tuberculosis complex test 
positive 
1 (<1%) 0 0 0 1 (<1%) 
Neutrophil count decreased 0 0 1 (<1%) 0 1 (<1%) 
Spleen palpable 1 (<1%) 0 0 0 1 (<1%) 
Weight decreased 1 (<1%) 0 0 0 1 (<1%) 
       
Eye disorders      
Any Event 22 (5%) 1 (<1%) 0 0 23 (6%) 
Conjunctivitis 13 (3%) 1 (<1%) 0 0 14 (3%) 
Blepharitis 2 (<1%) 0 0 0 2 (<1%) 
Dry eye 1 (<1%) 0 0 0 1 (<1%) 
Eye swelling 1 (<1%) 0 0 0 1 (<1%) 
Eyelid oedema 1 (<1%) 0 0 0 1 (<1%) 
Ocular hyperaemia 1 (<1%) 0 0 0 1 (<1%) 
Photopsia 1 (<1%) 0 0 0 1 (<1%) 
Scleritis 1 (<1%) 0 0 0 1 (<1%) 
Vision blurred 1 (<1%) 0 0 0 1 (<1%) 
Visual acuity reduced 1 (<1%) 0 0 0 1 (<1%) 
       
Ear and labyrinth disorders      
Any Event 8 (2%) 4 (<1%) 0 0 12 (3%) 
Tinnitus 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Cerumen impaction 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Ear discomfort 2 (<1%) 0 0 0 2 (<1%) 
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Vertigo 2 (<1%) 0 0 0 2 (<1%) 
Deafness bilateral 1 (<1%) 0 0 0 1 (<1%) 
Ear pain 0 1 (<1%) 0 0 1 (<1%) 
Tympanic membrane perforation 0 1 (<1%) 0 0 1 (<1%) 
       
Renal and urinary disorders      
Any Event 13 (3%) 3 (<1%) 1 (<1%) 0 17 (4%) 
Dysuria 4 (<1%) 0 0 0 4 (<1%) 
Haematuria 2 (<1%) 0 0 0 2 (<1%) 
Nephrolithiasis 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Choluria 1 (<1%) 0 0 0 1 (<1%) 
Chromaturia 1 (<1%) 0 0 0 1 (<1%) 
Micturition urgency 1 (<1%) 0 0 0 1 (<1%) 
Polyuria 1 (<1%) 0 0 0 1 (<1%) 
Renal cyst 0 0 1 (<1%) 0 1 (<1%) 
Renal failure 1 (<1%) 0 0 0 1 (<1%) 
Renal pain 1 (<1%) 0 0 0 1 (<1%) 
Urethral discharge 0 1 (<1%) 0 0 1 (<1%) 
Urinary incontinence 0 1 (<1%) 0 0 1 (<1%) 
Urinary retention 1 (<1%) 0 0 0 1 (<1%) 
       
Immune system disorders      
Any Event 10 (2%) 5 (1%) 1 (<1%) 0 16 (4%) 
Seasonal allergy 7 (2%) 3 (<1%) 0 0 10 (2%) 
Hypersensitivity 2 (<1%) 0 1 (<1%) 0 3 (<1%) 
Allergy to arthropod bite 1 (<1%) 0 0 0 1 (<1%) 
Drug hypersensitivity 0 1 (<1%) 0 0 1 (<1%) 
Immune reconstitution syndrome 0 1 (<1%) 0 0 1 (<1%) 
       
Vascular disorders      
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Any Event 9 (2%) 5 (1%) 0 0 14 (3%) 
Hypertension 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Flushing 2 (<1%) 0 0 0 2 (<1%) 
Arterial disorder 0 1 (<1%) 0 0 1 (<1%) 
Essential hypertension 0 1 (<1%) 0 0 1 (<1%) 
Haematoma 1 (<1%) 0 0 0 1 (<1%) 
Hot flush 1 (<1%) 0 0 0 1 (<1%) 
Orthostatic hypotension 0 1 (<1%) 0 0 1 (<1%) 
Peripheral coldness 1 (<1%) 0 0 0 1 (<1%) 
Peripheral vascular disorder 1 (<1%) 0 0 0 1 (<1%) 
       
Blood and lymphatic system disorders      
Any Event 11 (3%) 6 (1%) 1 (<1%) 0 18 (4%) 
Lymphadenopathy 9 (2%) 2 (<1%) 0 0 11 (3%) 
Neutropenia 0 2 (<1%) 0 0 2 (<1%) 
Anaemia 1 (<1%) 0 0 0 1 (<1%) 
Febrile neutropenia 0 0 1 (<1%) 0 1 (<1%) 
Iron deficiency anaemia 0 1 (<1%) 0 0 1 (<1%) 
Splenic cyst 0 1 (<1%) 0 0 1 (<1%) 
Splenomegaly 1 (<1%) 0 0 0 1 (<1%) 
       
Cardiac disorders      
Any Event 5 (1%) 3 (<1%) 1 (<1%) 0 9 (2%) 
Tachycardia 4 (<1%) 0 0 0 4 (<1%) 
Palpitations 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Cardiac disorder 0 1 (<1%) 0 0 1 (<1%) 
Cardiac failure congestive 0 0 1 (<1%) 0 1 (<1%) 
Supraventricular tachycardia 0 1 (<1%) 0 0 1 (<1%) 
       
Endocrine disorders      
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Treatment: DTG 50 mg +ABC/3TC QD (N=414)                                                                      
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Any Event 3 (<1%) 0 0 0 3 (<1%) 
Testicular failure 2 (<1%) 0 0 0 2 (<1%) 
Hyperthyroidism 1 (<1%) 0 0 0 1 (<1%) 
    
 
Treatment: Atripla QD (N=419)                                                                                
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 




58 (14%) 10 (2%) 387 
(92%) 
       
Infections and infestations      
Any Event 127 
(30%) 
77 (18%) 5 (1%) 2 (<1%) 211 
(50%) 
Nasopharyngitis 52 (12%) 8 (2%) 0 0 60 (14%) 
Upper respiratory tract infection 34 (8%) 9 (2%) 0 0 43 (10%) 
Syphilis 11 (3%) 6 (1%) 0 0 17 (4%) 
Bronchitis 4 (<1%) 10 (2%) 1 (<1%) 0 15 (4%) 
Gastroenteritis 10 (2%) 2 (<1%) 0 0 12 (3%) 
Urinary tract infection 9 (2%) 3 (<1%) 0 0 12 (3%) 
Sinusitis 8 (2%) 3 (<1%) 0 0 11 (3%) 
Folliculitis 8 (2%) 2 (<1%) 0 0 10 (2%) 
Herpes zoster 4 (<1%) 4 (<1%) 0 0 8 (2%) 
Pharyngitis 8 (2%) 0 0 0 8 (2%) 
Cellulitis 3 (<1%) 3 (<1%) 0 0 6 (1%) 
Influenza 2 (<1%) 4 (<1%) 0 0 6 (1%) 
Paronychia 3 (<1%) 3 (<1%) 0 0 6 (1%) 
Tonsillitis 5 (1%) 1 (<1%) 0 0 6 (1%) 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Acute sinusitis 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Chlamydial infection 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Furuncle 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Oral herpes 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Giardiasis 1 (<1%) 3 (<1%) 0 0 4 (<1%) 
Gonorrhoea 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Molluscum contagiosum 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Body tinea 3 (<1%) 0 0 0 3 (<1%) 
Gastroenteritis viral 3 (<1%) 0 0 0 3 (<1%) 
Herpes simplex 3 (<1%) 0 0 0 3 (<1%) 
Laryngitis 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Pneumonia 0 1 (<1%) 1 (<1%) 1 (<1%) 3 (<1%) 
Secondary syphilis 3 (<1%) 0 0 0 3 (<1%) 
Staphylococcal abscess 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Staphylococcal infection 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Urethritis 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Anal chlamydia infection 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Fungal skin infection 2 (<1%) 0 0 0 2 (<1%) 
Genital herpes 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Lymphogranuloma venereum 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Oropharyngeal gonococcal infection 2 (<1%) 0 0 0 2 (<1%) 
Proctitis chlamydial 2 (<1%) 0 0 0 2 (<1%) 
Respiratory tract infection 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Subcutaneous abscess 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Tinea infection 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Tinea pedis 2 (<1%) 0 0 0 2 (<1%) 
Tooth abscess 0 2 (<1%) 0 0 2 (<1%) 
Tooth infection 0 2 (<1%) 0 0 2 (<1%) 
Urethritis gonococcal 2 (<1%) 0 0 0 2 (<1%) 
Vaginal infection 2 (<1%) 0 0 0 2 (<1%) 
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Treatment: Atripla QD (N=419)                                                                                
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Vaginitis bacterial 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Viral infection 2 (<1%) 0 0 0 2 (<1%) 
Viral upper respiratory tract infection 2 (<1%) 0 0 0 2 (<1%) 
Abscess limb 0 1 (<1%) 0 0 1 (<1%) 
Acarodermatitis 1 (<1%) 0 0 0 1 (<1%) 
Acute tonsillitis 1 (<1%) 0 0 0 1 (<1%) 
Amoebiasis 1 (<1%) 0 0 0 1 (<1%) 
Anisakiasis 0 1 (<1%) 0 0 1 (<1%) 
Aspergillosis 0 0 0 1 (<1%) 1 (<1%) 
Bacteraemia 0 1 (<1%) 0 0 1 (<1%) 
Bacteriuria 1 (<1%) 0 0 0 1 (<1%) 
Bronchopulmonary aspergillosis 0 0 1 (<1%) 0 1 (<1%) 
Cellulitis of male external genital organ 1 (<1%) 0 0 0 1 (<1%) 
Cellulitis staphylococcal 1 (<1%) 0 0 0 1 (<1%) 
Cystitis 0 1 (<1%) 0 0 1 (<1%) 
Diarrhoea infectious 1 (<1%) 0 0 0 1 (<1%) 
Ear infection 1 (<1%) 0 0 0 1 (<1%) 
Eczema infected 1 (<1%) 0 0 0 1 (<1%) 
Enterobiasis 1 (<1%) 0 0 0 1 (<1%) 
Epiglottitis 0 1 (<1%) 0 0 1 (<1%) 
Escherichia urinary tract infection 0 1 (<1%) 0 0 1 (<1%) 
Gastroenteritis shigella 1 (<1%) 0 0 0 1 (<1%) 
Genital candidiasis 1 (<1%) 0 0 0 1 (<1%) 
Genital infection fungal 1 (<1%) 0 0 0 1 (<1%) 
Gingival infection 1 (<1%) 0 0 0 1 (<1%) 
Groin abscess 0 1 (<1%) 0 0 1 (<1%) 
Hepatitis C 0 0 1 (<1%) 0 1 (<1%) 
Hordeolum 0 1 (<1%) 0 0 1 (<1%) 
Impetigo 0 1 (<1%) 0 0 1 (<1%) 
Kidney infection 0 1 (<1%) 0 0 1 (<1%) 
Page 40 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Latent syphilis 1 (<1%) 0 0 0 1 (<1%) 
Latent tuberculosis 1 (<1%) 0 0 0 1 (<1%) 
Lobar pneumonia 0 1 (<1%) 0 0 1 (<1%) 
Localised infection 0 1 (<1%) 0 0 1 (<1%) 
Lower respiratory tract infection 1 (<1%) 0 0 0 1 (<1%) 
Meningitis cryptococcal 0 1 (<1%) 0 0 1 (<1%) 
Neutropenic infection 1 (<1%) 0 0 0 1 (<1%) 
Onychomycosis 0 1 (<1%) 0 0 1 (<1%) 
Otitis externa 0 1 (<1%) 0 0 1 (<1%) 
Otitis media 0 1 (<1%) 0 0 1 (<1%) 
Papilloma viral infection 1 (<1%) 0 0 0 1 (<1%) 
Periorbital cellulitis 0 1 (<1%) 0 0 1 (<1%) 
Pharyngotonsillitis 0 1 (<1%) 0 0 1 (<1%) 
Pneumococcal sepsis 0 0 1 (<1%) 0 1 (<1%) 
Pneumonia bacterial 1 (<1%) 0 0 0 1 (<1%) 
Proctitis bacterial 0 1 (<1%) 0 0 1 (<1%) 
Proctitis gonococcal 1 (<1%) 0 0 0 1 (<1%) 
Prostate infection 1 (<1%) 0 0 0 1 (<1%) 
Pyelonephritis 0 1 (<1%) 0 0 1 (<1%) 
Rectal abscess 0 1 (<1%) 0 0 1 (<1%) 
Respiratory tract infection viral 0 1 (<1%) 0 0 1 (<1%) 
Rhinitis 1 (<1%) 0 0 0 1 (<1%) 
Scrotal abscess 0 0 1 (<1%) 0 1 (<1%) 
Sepsis 0 0 0 1 (<1%) 1 (<1%) 
Septic shock 0 0 0 1 (<1%) 1 (<1%) 
Sexually transmitted disease 1 (<1%) 0 0 0 1 (<1%) 
Skin infection 0 1 (<1%) 0 0 1 (<1%) 
Staphylococcal skin infection 1 (<1%) 0 0 0 1 (<1%) 
Systemic candida 0 0 0 1 (<1%) 1 (<1%) 
Tinea barbae 1 (<1%) 0 0 0 1 (<1%) 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Tinea capitis 1 (<1%) 0 0 0 1 (<1%) 
Trichomoniasis 1 (<1%) 0 0 0 1 (<1%) 
Urethritis chlamydial 1 (<1%) 0 0 0 1 (<1%) 
Vulvovaginal candidiasis 1 (<1%) 0 0 0 1 (<1%) 
       
Gastrointestinal disorders      
Any Event 123 
(29%) 
54 (13%) 7 (2%) 0 184 
(44%) 
Diarrhoea 58 (14%) 15 (4%) 2 (<1%) 0 75 (18%) 
Nausea 44 (11%) 13 (3%) 0 0 57 (14%) 
Vomiting 13 (3%) 6 (1%) 0 0 19 (5%) 
Abdominal pain upper 13 (3%) 1 (<1%) 0 0 14 (3%) 
Abdominal pain 8 (2%) 4 (<1%) 1 (<1%) 0 13 (3%) 
Constipation 8 (2%) 2 (<1%) 0 0 10 (2%) 
Flatulence 7 (2%) 2 (<1%) 1 (<1%) 0 10 (2%) 
Abdominal distension 7 (2%) 1 (<1%) 0 0 8 (2%) 
Haemorrhoids 6 (1%) 2 (<1%) 0 0 8 (2%) 
Toothache 5 (1%) 1 (<1%) 2 (<1%) 0 8 (2%) 
Dyspepsia 5 (1%) 1 (<1%) 0 0 6 (1%) 
Anal fissure 4 (<1%) 0 0 0 4 (<1%) 
Anogenital dysplasia 1 (<1%) 2 (<1%) 1 (<1%) 0 4 (<1%) 
Proctalgia 1 (<1%) 3 (<1%) 0 0 4 (<1%) 
Abdominal pain lower 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Food poisoning 1 (<1%) 1 (<1%) 1 (<1%) 0 3 (<1%) 
Oral pain 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Proctitis 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Abdominal discomfort 2 (<1%) 0 0 0 2 (<1%) 
Anal fistula 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Anal pruritus 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Anal ulcer 2 (<1%) 0 0 0 2 (<1%) 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Aphthous stomatitis 2 (<1%) 0 0 0 2 (<1%) 
Dental caries 0 1 (<1%) 1 (<1%) 0 2 (<1%) 
Dry mouth 2 (<1%) 0 0 0 2 (<1%) 
Gingivitis 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Glossitis 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Haematochezia 2 (<1%) 0 0 0 2 (<1%) 
Rectal haemorrhage 2 (<1%) 0 0 0 2 (<1%) 
Anal haemorrhage 1 (<1%) 0 0 0 1 (<1%) 
Anal inflammation 1 (<1%) 0 0 0 1 (<1%) 
Anal polyp 1 (<1%) 0 0 0 1 (<1%) 
Anorectal discomfort 1 (<1%) 0 0 0 1 (<1%) 
Breath odour 1 (<1%) 0 0 0 1 (<1%) 
Cheilitis 1 (<1%) 0 0 0 1 (<1%) 
Crohn's disease 1 (<1%) 0 0 0 1 (<1%) 
Dysphagia 1 (<1%) 0 0 0 1 (<1%) 
Enterocolitis 1 (<1%) 0 0 0 1 (<1%) 
Eructation 1 (<1%) 0 0 0 1 (<1%) 
Gastritis 1 (<1%) 0 0 0 1 (<1%) 
Gastrointestinal pain 0 0 1 (<1%) 0 1 (<1%) 
Gastrooesophageal reflux disease 1 (<1%) 0 0 0 1 (<1%) 
Hiatus hernia 0 1 (<1%) 0 0 1 (<1%) 
Lip swelling 0 1 (<1%) 0 0 1 (<1%) 
Mouth cyst 1 (<1%) 0 0 0 1 (<1%) 
Odynophagia 0 0 1 (<1%) 0 1 (<1%) 
Proctocolitis 0 1 (<1%) 0 0 1 (<1%) 
Rectal fissure 0 1 (<1%) 0 0 1 (<1%) 
Salivary hypersecretion 1 (<1%) 0 0 0 1 (<1%) 
Stomatitis 0 1 (<1%) 0 0 1 (<1%) 
Tongue ulceration 1 (<1%) 0 0 0 1 (<1%) 
Tooth disorder 0 1 (<1%) 0 0 1 (<1%) 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
       
Nervous system disorders      
Any Event 168 
(40%) 




18 (4%) 3 (<1%) 0 148 
(35%) 
Headache 43 (10%) 11 (3%) 2 (<1%) 0 56 (13%) 
Somnolence 19 (5%) 3 (<1%) 1 (<1%) 0 23 (5%) 
Paraesthesia 8 (2%) 0 0 0 8 (2%) 
Hypoaesthesia 6 (1%) 1 (<1%) 0 0 7 (2%) 
Hypersomnia 3 (<1%) 1 (<1%) 1 (<1%) 0 5 (1%) 
Disturbance in attention 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Dysgeusia 4 (<1%) 0 0 0 4 (<1%) 
Memory impairment 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Poor quality sleep 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Balance disorder 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Sciatica 2 (<1%) 0 1 (<1%) 0 3 (<1%) 
Syncope 3 (<1%) 0 0 0 3 (<1%) 
Amnesia 1 (<1%) 0 1 (<1%) 0 2 (<1%) 
Aphonia 2 (<1%) 0 0 0 2 (<1%) 
Migraine 2 (<1%) 0 0 0 2 (<1%) 
Sinus headache 2 (<1%) 0 0 0 2 (<1%) 
Tremor 2 (<1%) 0 0 0 2 (<1%) 
Cerebrovascular accident 0 0 0 1 (<1%) 1 (<1%) 
Cervicobrachial syndrome 1 (<1%) 0 0 0 1 (<1%) 
Convulsion 1 (<1%) 0 0 0 1 (<1%) 
Depressed level of consciousness 1 (<1%) 0 0 0 1 (<1%) 
Dizziness postural 1 (<1%) 0 0 0 1 (<1%) 
Dystonia 1 (<1%) 0 0 0 1 (<1%) 
Hemiparesis 0 1 (<1%) 0 0 1 (<1%) 
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Treatment: Atripla QD (N=419)                                                                                
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Hydrocephalus 0 0 1 (<1%) 0 1 (<1%) 
Intercostal neuralgia 0 1 (<1%) 0 0 1 (<1%) 
Loss of consciousness 0 1 (<1%) 0 0 1 (<1%) 
Mental impairment 0 1 (<1%) 0 0 1 (<1%) 
Muscle contractions involuntary 1 (<1%) 0 0 0 1 (<1%) 
Myelopathy 1 (<1%) 0 0 0 1 (<1%) 
Neuralgia 1 (<1%) 0 0 0 1 (<1%) 
Neuropathy peripheral 0 0 1 (<1%) 0 1 (<1%) 
Neurotoxicity 0 0 1 (<1%) 0 1 (<1%) 
Restless legs syndrome 1 (<1%) 0 0 0 1 (<1%) 
Sensory loss 1 (<1%) 0 0 0 1 (<1%) 
VIIth nerve paralysis 0 1 (<1%) 0 0 1 (<1%) 
       
Psychiatric disorders      
Any Event 111 
(26%) 
42 (10%) 13 (3%) 2 (<1%) 168 
(40%) 
Abnormal dreams 63 (15%) 8 (2%) 1 (<1%) 0 72 (17%) 
Insomnia 27 (6%) 16 (4%) 0 0 43 (10%) 
Anxiety 15 (4%) 10 (2%) 2 (<1%) 0 27 (6%) 
Depression 12 (3%) 9 (2%) 5 (1%) 0 26 (6%) 
Nightmare 12 (3%) 4 (<1%) 1 (<1%) 0 17 (4%) 
Sleep disorder 8 (2%) 3 (<1%) 0 0 11 (3%) 
Depressed mood 7 (2%) 0 0 0 7 (2%) 
Libido decreased 4 (<1%) 0 0 0 4 (<1%) 
Suicidal ideation 1 (<1%) 1 (<1%) 1 (<1%) 1 (<1%) 4 (<1%) 
Anger 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Nervousness 3 (<1%) 0 0 0 3 (<1%) 
Affect lability 2 (<1%) 0 0 0 2 (<1%) 
Alcohol abuse 0 0 1 (<1%) 1 (<1%) 2 (<1%) 
Confusional state 2 (<1%) 0 0 0 2 (<1%) 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Depressive symptom 0 2 (<1%) 0 0 2 (<1%) 
Disorientation 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Euphoric mood 0 2 (<1%) 0 0 2 (<1%) 
Hallucination, visual 0 1 (<1%) 1 (<1%) 0 2 (<1%) 
Homicidal ideation 0 1 (<1%) 1 (<1%) 0 2 (<1%) 
Mood altered 2 (<1%) 0 0 0 2 (<1%) 
Stress 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Acute stress disorder 1 (<1%) 0 0 0 1 (<1%) 
Affective disorder 1 (<1%) 0 0 0 1 (<1%) 
Agitation 1 (<1%) 0 0 0 1 (<1%) 
Alcoholism 0 0 0 1 (<1%) 1 (<1%) 
Bipolar I disorder 0 0 1 (<1%) 0 1 (<1%) 
Bipolar II disorder 0 1 (<1%) 0 0 1 (<1%) 
Claustrophobia 1 (<1%) 0 0 0 1 (<1%) 
Drug abuse 1 (<1%) 0 0 0 1 (<1%) 
Emotional disorder 0 1 (<1%) 0 0 1 (<1%) 
Mania 0 0 1 (<1%) 0 1 (<1%) 
Middle insomnia 1 (<1%) 0 0 0 1 (<1%) 
Mood swings 1 (<1%) 0 0 0 1 (<1%) 
Paranoia 0 0 0 1 (<1%) 1 (<1%) 
Somnambulism 1 (<1%) 0 0 0 1 (<1%) 
Substance abuse 0 1 (<1%) 0 0 1 (<1%) 
Suicidal behaviour 0 0 0 1 (<1%) 1 (<1%) 
Suicide attempt 0 0 1 (<1%) 0 1 (<1%) 
Terminal insomnia 1 (<1%) 0 0 0 1 (<1%) 
Thinking abnormal 1 (<1%) 0 0 0 1 (<1%) 
Withdrawal syndrome 0 1 (<1%) 0 0 1 (<1%) 
       
Skin and subcutaneous tissue disorders      
Any Event 84 (20%) 46 (11%) 3 (<1%) 0 133 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
(32%) 
Rash 39 (9%) 19 (5%) 0 0 58 (14%) 
Pruritus 9 (2%) 4 (<1%) 0 0 13 (3%) 
Night sweats 10 (2%) 2 (<1%) 0 0 12 (3%) 
Alopecia 6 (1%) 2 (<1%) 0 0 8 (2%) 
Rash generalised 6 (1%) 2 (<1%) 0 0 8 (2%) 
Dermatitis 5 (1%) 2 (<1%) 0 0 7 (2%) 
Dry skin 5 (1%) 2 (<1%) 0 0 7 (2%) 
Acne 5 (1%) 0 0 0 5 (1%) 
Eczema 3 (<1%) 1 (<1%) 1 (<1%) 0 5 (1%) 
Rash maculo-papular 0 5 (1%) 0 0 5 (1%) 
Hyperhidrosis 4 (<1%) 0 0 0 4 (<1%) 
Drug eruption 0 2 (<1%) 1 (<1%) 0 3 (<1%) 
Erythema 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Seborrhoeic dermatitis 2 (<1%) 0 1 (<1%) 0 3 (<1%) 
Dermal cyst 2 (<1%) 0 0 0 2 (<1%) 
Dermatitis allergic 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Dermatitis contact 2 (<1%) 0 0 0 2 (<1%) 
Hyperkeratosis 2 (<1%) 0 0 0 2 (<1%) 
Nail discolouration 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Prurigo 0 2 (<1%) 0 0 2 (<1%) 
Skin lesion 2 (<1%) 0 0 0 2 (<1%) 
Angioedema 1 (<1%) 0 0 0 1 (<1%) 
Blister 1 (<1%) 0 0 0 1 (<1%) 
Cold sweat 0 1 (<1%) 0 0 1 (<1%) 
Dermatitis atopic 1 (<1%) 0 0 0 1 (<1%) 
Dyshidrosis 1 (<1%) 0 0 0 1 (<1%) 
Hair texture abnormal 1 (<1%) 0 0 0 1 (<1%) 
Increased tendency to bruise 1 (<1%) 0 0 0 1 (<1%) 
Ingrown hair 1 (<1%) 0 0 0 1 (<1%) 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Livedo reticularis 1 (<1%) 0 0 0 1 (<1%) 
Neurodermatitis 1 (<1%) 0 0 0 1 (<1%) 
Onychomalacia 1 (<1%) 0 0 0 1 (<1%) 
Papule 1 (<1%) 0 0 0 1 (<1%) 
Pruritus generalised 0 1 (<1%) 0 0 1 (<1%) 
Rash macular 0 1 (<1%) 0 0 1 (<1%) 
Rash pruritic 1 (<1%) 0 0 0 1 (<1%) 
Rosacea 1 (<1%) 0 0 0 1 (<1%) 
Sebaceous hyperplasia 1 (<1%) 0 0 0 1 (<1%) 
Seborrhoea 0 1 (<1%) 0 0 1 (<1%) 
Skin exfoliation 1 (<1%) 0 0 0 1 (<1%) 
Skin ulcer 1 (<1%) 0 0 0 1 (<1%) 
Urticaria 1 (<1%) 0 0 0 1 (<1%) 
Urticaria thermal 1 (<1%) 0 0 0 1 (<1%) 
Xeroderma 1 (<1%) 0 0 0 1 (<1%) 
       
General disorders and administration site 
conditions 
     
Any Event 72 (17%) 27 (6%) 3 (<1%) 0 102 
(24%) 
Fatigue 41 (10%) 7 (2%) 2 (<1%) 0 50 (12%) 
Pyrexia 16 (4%) 6 (1%) 0 0 22 (5%) 
Asthenia 8 (2%) 5 (1%) 1 (<1%) 0 14 (3%) 
Influenza like illness 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Pain 4 (<1%) 0 0 0 4 (<1%) 
Chest pain 3 (<1%) 0 0 0 3 (<1%) 
Feeling drunk 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Oedema peripheral 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Chills 2 (<1%) 0 0 0 2 (<1%) 
Cyst 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Page 48 
 
Treatment: Atripla QD (N=419)                                                                                
  Maximum Toxicity 
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System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Energy increased 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Feeling abnormal 2 (<1%) 0 0 0 2 (<1%) 
Irritability 0 2 (<1%) 0 0 2 (<1%) 
Malaise 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Thirst 0 2 (<1%) 0 0 2 (<1%) 
Chronic fatigue syndrome 1 (<1%) 0 0 0 1 (<1%) 
Discomfort 1 (<1%) 0 0 0 1 (<1%) 
Feeling hot 1 (<1%) 0 0 0 1 (<1%) 
Hernia 1 (<1%) 0 0 0 1 (<1%) 
Local swelling 0 1 (<1%) 0 0 1 (<1%) 
Mass 1 (<1%) 0 0 0 1 (<1%) 
Non-cardiac chest pain 1 (<1%) 0 0 0 1 (<1%) 
       
Musculoskeletal and connective tissue 
disorders 
     
Any Event 51 (12%) 29 (7%) 2 (<1%) 0 82 (20%) 
Back pain 9 (2%) 7 (2%) 1 (<1%) 0 17 (4%) 
Arthralgia 7 (2%) 8 (2%) 1 (<1%) 0 16 (4%) 
Myalgia 15 (4%) 1 (<1%) 0 0 16 (4%) 
Pain in extremity 6 (1%) 4 (<1%) 0 0 10 (2%) 
Muscle twitching 3 (<1%) 0 0 0 3 (<1%) 
Musculoskeletal pain 3 (<1%) 0 0 0 3 (<1%) 
Tendonitis 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Coccydynia 2 (<1%) 0 0 0 2 (<1%) 
Flank pain 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Groin pain 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Joint swelling 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Muscle spasms 2 (<1%) 0 0 0 2 (<1%) 
Neck pain 2 (<1%) 0 0 0 2 (<1%) 
Rotator cuff syndrome 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
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System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Costochondritis 1 (<1%) 0 0 0 1 (<1%) 
Kyphoscoliosis 0 1 (<1%) 0 0 1 (<1%) 
Muscle atrophy 0 1 (<1%) 0 0 1 (<1%) 
Muscle tightness 1 (<1%) 0 0 0 1 (<1%) 
Myositis 1 (<1%) 0 0 0 1 (<1%) 
Osteochondrosis 1 (<1%) 0 0 0 1 (<1%) 
Osteopenia 1 (<1%) 0 0 0 1 (<1%) 
Osteoporosis 0 1 (<1%) 0 0 1 (<1%) 
Patellofemoral pain syndrome 1 (<1%) 0 0 0 1 (<1%) 
Spinal disorder 0 1 (<1%) 0 0 1 (<1%) 
Synovitis 0 1 (<1%) 0 0 1 (<1%) 
       
Respiratory, thoracic and mediastinal 
disorders 
     
Any Event 58 (14%) 13 (3%) 5 (1%) 1 (<1%) 77 (18%) 
Cough 26 (6%) 3 (<1%) 0 0 29 (7%) 
Oropharyngeal pain 10 (2%) 2 (<1%) 2 (<1%) 0 14 (3%) 
Nasal congestion 9 (2%) 0 0 0 9 (2%) 
Productive cough 5 (1%) 0 0 0 5 (1%) 
Rhinitis allergic 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Rhinorrhoea 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Sinus congestion 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Dyspnoea 4 (<1%) 0 0 0 4 (<1%) 
Sneezing 4 (<1%) 0 0 0 4 (<1%) 
Asthma 1 (<1%) 1 (<1%) 1 (<1%) 0 3 (<1%) 
Throat irritation 3 (<1%) 0 0 0 3 (<1%) 
Nasal discomfort 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Respiratory distress 0 0 2 (<1%) 0 2 (<1%) 
Allergic sinusitis 0 1 (<1%) 0 0 1 (<1%) 
Chronic obstructive pulmonary disease 0 1 (<1%) 0 0 1 (<1%) 
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System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Dyspnoea at rest 1 (<1%) 0 0 0 1 (<1%) 
Dyspnoea exertional 1 (<1%) 0 0 0 1 (<1%) 
Nasal ulcer 1 (<1%) 0 0 0 1 (<1%) 
Pharyngeal oedema 0 1 (<1%) 0 0 1 (<1%) 
Pharyngeal ulceration 1 (<1%) 0 0 0 1 (<1%) 
Pneumonia aspiration 0 0 1 (<1%) 0 1 (<1%) 
Pulmonary cavitation 0 1 (<1%) 0 0 1 (<1%) 
Respiratory disorder 1 (<1%) 0 0 0 1 (<1%) 
Respiratory failure 0 0 0 1 (<1%) 1 (<1%) 
Respiratory tract congestion 1 (<1%) 0 0 0 1 (<1%) 
Respiratory tract irritation 1 (<1%) 0 0 0 1 (<1%) 
Sleep apnoea syndrome 0 1 (<1%) 0 0 1 (<1%) 
Sputum discoloured 1 (<1%) 0 0 0 1 (<1%) 
Sputum increased 1 (<1%) 0 0 0 1 (<1%) 
Tonsillar hypertrophy 1 (<1%) 0 0 0 1 (<1%) 
       
Injury, poisoning and procedural 
complications 
     
Any Event 26 (6%) 18 (4%) 3 (<1%) 2 (<1%) 49 (12%) 
Contusion 4 (<1%) 2 (<1%) 0 0 6 (1%) 
Ligament sprain 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Procedural pain 1 (<1%) 4 (<1%) 0 0 5 (1%) 
Laceration 2 (<1%) 2 (<1%) 0 0 4 (<1%) 
Hand fracture 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Muscle strain 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Animal bite 2 (<1%) 0 0 0 2 (<1%) 
Arthropod bite 2 (<1%) 0 0 0 2 (<1%) 
Epicondylitis 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Joint injury 0 2 (<1%) 0 0 2 (<1%) 
Limb injury 2 (<1%) 0 0 0 2 (<1%) 
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System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Muscle injury 0 1 (<1%) 0 1 (<1%) 2 (<1%) 
Tooth fracture 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Arthropod sting 1 (<1%) 0 0 0 1 (<1%) 
Excoriation 1 (<1%) 0 0 0 1 (<1%) 
Exposure to communicable disease 1 (<1%) 0 0 0 1 (<1%) 
Eye injury 1 (<1%) 0 0 0 1 (<1%) 
Fall 1 (<1%) 0 0 0 1 (<1%) 
Foot fracture 0 0 1 (<1%) 0 1 (<1%) 
Limb crushing injury 0 1 (<1%) 0 0 1 (<1%) 
Meniscus lesion 0 1 (<1%) 0 0 1 (<1%) 
Muscle rupture 1 (<1%) 0 0 0 1 (<1%) 
Overdose 0 0 1 (<1%) 0 1 (<1%) 
Post procedural haemorrhage 1 (<1%) 0 0 0 1 (<1%) 
Rib fracture 0 1 (<1%) 0 0 1 (<1%) 
Road traffic accident 0 1 (<1%) 0 0 1 (<1%) 
Sunburn 1 (<1%) 0 0 0 1 (<1%) 
Upper limb fracture 0 0 1 (<1%) 0 1 (<1%) 
Vascular pseudoaneurysm 0 0 0 1 (<1%) 1 (<1%) 
Wound 0 1 (<1%) 0 0 1 (<1%) 
       
Metabolism and nutrition disorders      
Any Event 23 (5%) 7 (2%) 6 (1%) 1 (<1%) 37 (9%) 
Decreased appetite 13 (3%) 1 (<1%) 1 (<1%) 0 15 (4%) 
Vitamin D deficiency 5 (1%) 0 0 0 5 (1%) 
Hypercholesterolaemia 1 (<1%) 1 (<1%) 1 (<1%) 0 3 (<1%) 
Alcohol intolerance 2 (<1%) 0 0 0 2 (<1%) 
Gout 0 1 (<1%) 1 (<1%) 0 2 (<1%) 
Hypertriglyceridaemia 0 1 (<1%) 0 1 (<1%) 2 (<1%) 
Increased appetite 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Abnormal loss of weight 0 0 1 (<1%) 0 1 (<1%) 
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Treatment: Atripla QD (N=419)                                                                                
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Dehydration 1 (<1%) 0 0 0 1 (<1%) 
Dyslipidaemia 1 (<1%) 0 0 0 1 (<1%) 
Food intolerance 0 1 (<1%) 0 0 1 (<1%) 
Hyperglycaemia 0 0 1 (<1%) 0 1 (<1%) 
Hypophosphataemia 0 0 1 (<1%) 0 1 (<1%) 
Type 2 diabetes mellitus 0 1 (<1%) 0 0 1 (<1%) 
       
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
     
Any Event 22 (5%) 4 (<1%) 1 (<1%) 0 27 (6%) 
Anogenital warts 11 (3%) 2 (<1%) 0 0 13 (3%) 
Skin papilloma 3 (<1%) 2 (<1%) 0 0 5 (1%) 
Melanocytic naevus 2 (<1%) 0 0 0 2 (<1%) 
Chondroma 1 (<1%) 0 0 0 1 (<1%) 
Fibroma 1 (<1%) 0 0 0 1 (<1%) 
Haemangioma of skin 1 (<1%) 0 0 0 1 (<1%) 
Malignant melanoma 0 1 (<1%) 0 0 1 (<1%) 
Morton's neuroma 1 (<1%) 0 0 0 1 (<1%) 
Ovarian cancer 0 0 1 (<1%) 0 1 (<1%) 
Seborrhoeic keratosis 1 (<1%) 0 0 0 1 (<1%) 
Thyroid neoplasm 1 (<1%) 0 0 0 1 (<1%) 
       
Reproductive system and breast 
disorders 
     
Any Event 18 (4%) 6 (1%) 0 0 24 (6%) 
Erectile dysfunction 4 (<1%) 1 (<1%) 0 0 5 (1%) 
Gynaecomastia 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Prostatitis 2 (<1%) 0 0 0 2 (<1%) 
Breast mass 1 (<1%) 0 0 0 1 (<1%) 
Breast pain 0 1 (<1%) 0 0 1 (<1%) 
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Treatment: Atripla QD (N=419)                                                                                
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Cervical dysplasia 0 1 (<1%) 0 0 1 (<1%) 
Menometrorrhagia 0 1 (<1%) 0 0 1 (<1%) 
Menorrhagia 1 (<1%) 0 0 0 1 (<1%) 
Menstrual disorder 1 (<1%) 0 0 0 1 (<1%) 
Menstruation irregular 1 (<1%) 0 0 0 1 (<1%) 
Orchitis noninfective 1 (<1%) 0 0 0 1 (<1%) 
Penile pain 1 (<1%) 0 0 0 1 (<1%) 
Scrotal pain 0 1 (<1%) 0 0 1 (<1%) 
Testicular disorder 1 (<1%) 0 0 0 1 (<1%) 
Testicular pain 1 (<1%) 0 0 0 1 (<1%) 
Vaginal discharge 1 (<1%) 0 0 0 1 (<1%) 
Vaginal odour 1 (<1%) 0 0 0 1 (<1%) 
Vulvovaginal pruritus 1 (<1%) 0 0 0 1 (<1%) 
       
Investigations      
Any Event 8 (2%) 11 (3%) 6 (1%) 2 (<1%) 27 (6%) 
Blood creatine phosphokinase increased 0 2 (<1%) 2 (<1%) 2 (<1%) 6 (1%) 
Weight decreased 3 (<1%) 1 (<1%) 1 (<1%) 0 5 (1%) 
Alanine aminotransferase increased 0 3 (<1%) 0 0 3 (<1%) 
Weight increased 2 (<1%) 1 (<1%) 0 0 3 (<1%) 
Blood pressure increased 2 (<1%) 0 0 0 2 (<1%) 
Aspartate aminotransferase increased 0 1 (<1%) 0 0 1 (<1%) 
Blood bilirubin increased 0 0 1 (<1%) 0 1 (<1%) 
Blood creatinine increased 0 1 (<1%) 0 0 1 (<1%) 
Blood phosphorus decreased 0 0 1 (<1%) 0 1 (<1%) 
Blood potassium increased 0 0 1 (<1%) 0 1 (<1%) 
Human papilloma virus test positive 1 (<1%) 0 0 0 1 (<1%) 
Liver function test abnormal 1 (<1%) 0 0 0 1 (<1%) 
Platelet count decreased 0 1 (<1%) 0 0 1 (<1%) 
Smear cervix abnormal 1 (<1%) 0 0 0 1 (<1%) 
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Treatment: Atripla QD (N=419)                                                                                
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Treponema test positive 0 1 (<1%) 0 0 1 (<1%) 
Urine albumin/creatinine ratio increased 0 1 (<1%) 0 0 1 (<1%) 
       
Eye disorders      
Any Event 17 (4%) 3 (<1%) 0 0 20 (5%) 
Conjunctivitis 10 (2%) 2 (<1%) 0 0 12 (3%) 
Eye swelling 2 (<1%) 0 0 0 2 (<1%) 
Vision blurred 2 (<1%) 0 0 0 2 (<1%) 
Blepharitis 1 (<1%) 0 0 0 1 (<1%) 
Eye irritation 1 (<1%) 0 0 0 1 (<1%) 
Lacrimation increased 1 (<1%) 0 0 0 1 (<1%) 
Photophobia 1 (<1%) 0 0 0 1 (<1%) 
Presbyopia 1 (<1%) 0 0 0 1 (<1%) 
Visual acuity reduced 0 1 (<1%) 0 0 1 (<1%) 
       
Ear and labyrinth disorders      
Any Event 15 (4%) 10 (2%) 1 (<1%) 0 26 (6%) 
Vertigo 9 (2%) 6 (1%) 1 (<1%) 0 16 (4%) 
Cerumen impaction 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Ear pain 3 (<1%) 0 0 0 3 (<1%) 
Deafness unilateral 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Tinnitus 2 (<1%) 0 0 0 2 (<1%) 
Auricular swelling 0 1 (<1%) 0 0 1 (<1%) 
       
Renal and urinary disorders      
Any Event 13 (3%) 6 (1%) 1 (<1%) 1 (<1%) 21 (5%) 
Dysuria 3 (<1%) 1 (<1%) 0 0 4 (<1%) 
Nephrolithiasis 1 (<1%) 2 (<1%) 0 0 3 (<1%) 
Micturition urgency 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
Proteinuria 1 (<1%) 1 (<1%) 0 0 2 (<1%) 
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Treatment: Atripla QD (N=419)                                                                                
  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Renal failure 1 (<1%) 0 0 1 (<1%) 2 (<1%) 
Urethral discharge 2 (<1%) 0 0 0 2 (<1%) 
Bladder fibrosis 0 1 (<1%) 0 0 1 (<1%) 
Nocturia 1 (<1%) 0 0 0 1 (<1%) 
Pyuria 0 1 (<1%) 0 0 1 (<1%) 
Renal failure acute 0 1 (<1%) 0 0 1 (<1%) 
Renal failure chronic 0 0 1 (<1%) 0 1 (<1%) 
Urinary incontinence 1 (<1%) 0 0 0 1 (<1%) 
Urinary tract pain 1 (<1%) 0 0 0 1 (<1%) 
Urine odour abnormal 1 (<1%) 0 0 0 1 (<1%) 
       
Immune system disorders      
Any Event 9 (2%) 2 (<1%) 4 (<1%) 0 15 (4%) 
Seasonal allergy 6 (1%) 0 0 0 6 (1%) 
Hypersensitivity 0 0 3 (<1%) 0 3 (<1%) 
Drug hypersensitivity 1 (<1%) 0 1 (<1%) 0 2 (<1%) 
Immune reconstitution syndrome 0 2 (<1%) 0 0 2 (<1%) 
Multiple allergies 2 (<1%) 0 0 0 2 (<1%) 
       
Vascular disorders      
Any Event 11 (3%) 5 (1%) 1 (<1%) 0 17 (4%) 
Flushing 5 (1%) 1 (<1%) 0 0 6 (1%) 
Hypertension 2 (<1%) 2 (<1%) 0 0 4 (<1%) 
Hot flush 2 (<1%) 0 0 0 2 (<1%) 
Angiopathy 0 1 (<1%) 0 0 1 (<1%) 
Arterial disorder 1 (<1%) 0 0 0 1 (<1%) 
Deep vein thrombosis 0 0 1 (<1%) 0 1 (<1%) 
Hypotension 0 1 (<1%) 0 0 1 (<1%) 
Varicose vein 1 (<1%) 0 0 0 1 (<1%) 
       
Page 56 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Blood and lymphatic system disorders      
Any Event 6 (1%) 1 (<1%) 3 (<1%) 1 (<1%) 11 (3%) 
Anaemia 3 (<1%) 0 1 (<1%) 0 4 (<1%) 
Lymphadenopathy 3 (<1%) 0 1 (<1%) 0 4 (<1%) 
Neutropenia 0 1 (<1%) 0 1 (<1%) 2 (<1%) 
Disseminated intravascular coagulation 0 0 1 (<1%) 0 1 (<1%) 
       
Cardiac disorders      
Any Event 3 (<1%) 2 (<1%) 1 (<1%) 0 6 (1%) 
Palpitations 2 (<1%) 0 0 0 2 (<1%) 
Atrial fibrillation 0 0 1 (<1%) 0 1 (<1%) 
Atrial flutter 0 0 1 (<1%) 0 1 (<1%) 
Cardiac flutter 0 1 (<1%) 0 0 1 (<1%) 
Coronary artery disease 0 1 (<1%) 0 0 1 (<1%) 
Tachycardia 1 (<1%) 0 0 0 1 (<1%) 
       
Hepatobiliary disorders      
Any Event 0 2 (<1%) 1 (<1%) 0 3 (<1%) 
Autoimmune hepatitis 0 1 (<1%) 0 0 1 (<1%) 
Cholecystitis 0 0 1 (<1%) 0 1 (<1%) 
Cholelithiasis 0 1 (<1%) 0 0 1 (<1%) 
       
Pregnancy, puerperium and perinatal 
conditions 
     
Any Event 0 1 (<1%) 1 (<1%) 0 2 (<1%) 
Abortion spontaneous 0 1 (<1%) 0 0 1 (<1%) 
Ectopic pregnancy 0 0 1 (<1%) 0 1 (<1%) 
       
Congenital, familial and genetic 
disorders 
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  Maximum Toxicity 
  ----- 
 
System Organ Class 
Preferred Term 
Grade 1 Grade 2 Grade 3 Grade 4 Total 
Any Event 1 (<1%) 0 0 0 1 (<1%) 
Dermoid cyst 1 (<1%) 0 0 0 1 (<1%) 
       
Social circumstances      
Any Event 0 1 (<1%) 0 0 1 (<1%) 






















Table S6. Summary of Serious Adverse Events by System Organ Class 
 Protocol: ING114467  
Population: Safety  
Summary of Serious Adverse Events by System Organ Class 
 
System Organ Class 
Preferred Term 







ANY EVENT 37 (9%) 35 (8%) 
      
Infections and infestations     
Any event 13 (3%) 12 (3%) 
Pneumonia 2 (<1%) 2 (<1%) 
Bronchitis 1 (<1%) 1 (<1%) 
Syphilis 2 (<1%) 0 
Appendicitis 1 (<1%) 0 
Bacteraemia 0 1 (<1%) 
Cellulitis 0 1 (<1%) 
Gastroenteritis 0 1 (<1%) 
Infected dermal cyst 1 (<1%) 0 
Meningitis 1 (<1%) 0 
Meningitis cryptococcal 0 1 (<1%) 
Mycobacterium avium complex infection 1 (<1%) 0 
Neurosyphilis 1 (<1%) 0 
Pneumococcal sepsis 0 1 (<1%) 
Post procedural infection 1 (<1%) 0 
Postoperative wound infection 1 (<1%) 0 
Scrotal abscess 0 1 (<1%) 
Sepsis 0 1 (<1%) 
Septic shock 0 1 (<1%) 
Staphylococcal abscess 0 1 (<1%) 
Subcutaneous abscess 0 1 (<1%) 
Systemic candida 0 1 (<1%) 
Toxoplasmosis 1 (<1%) 0 
Tuberculosis 1 (<1%) 0 
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System Organ Class 
Preferred Term 







Viral infection 1 (<1%) 0 
      
Injury, poisoning and procedural complications     
Any event 8 (2%) 3 (<1%) 
Foot fracture 1 (<1%) 1 (<1%) 
Intentional overdose 2 (<1%) 0 
Head injury 1 (<1%) 0 
Humerus fracture 1 (<1%) 0 
Jaw fracture 1 (<1%) 0 
Overdose 0 1 (<1%) 
Road traffic accident 1 (<1%) 0 
Subdural haematoma 1 (<1%) 0 
Vascular pseudoaneurysm 0 1 (<1%) 
      
Psychiatric disorders     
Any event 3 (<1%) 8 (2%) 
Suicidal ideation 1 (<1%) 2 (<1%) 
Suicide attempt 2 (<1%) 1 (<1%) 
Depression 0 2 (<1%) 
Homicidal ideation 1 (<1%) 1 (<1%) 
Alcohol abuse 0 1 (<1%) 
Bipolar I disorder 0 1 (<1%) 
Hallucination, visual 0 1 (<1%) 
Mania 0 1 (<1%) 
Paranoia 0 1 (<1%) 
Suicidal behaviour 0 1 (<1%) 
      
Nervous system disorders     
Any event 3 (<1%) 3 (<1%) 
Cerebrovascular accident 1 (<1%) 1 (<1%) 
Carpal tunnel syndrome 1 (<1%) 0 
Convulsion 0 1 (<1%) 
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System Organ Class 
Preferred Term 







Grand mal convulsion 1 (<1%) 0 
Sciatica 0 1 (<1%) 
      
Respiratory, thoracic and mediastinal disorders     
Any event 2 (<1%) 4 (<1%) 
Respiratory distress 0 2 (<1%) 
Asthma 0 1 (<1%) 
Pleural effusion 1 (<1%) 0 
Pneumonia aspiration 0 1 (<1%) 
Respiratory failure 0 1 (<1%) 
Tonsillar disorder 1 (<1%) 0 
      
Blood and lymphatic system disorders     
Any event 1 (<1%) 3 (<1%) 
Anaemia 0 1 (<1%) 
Disseminated intravascular coagulation 0 1 (<1%) 
Febrile neutropenia 1 (<1%) 0 
Lymphadenopathy 0 1 (<1%) 
      
Cardiac disorders     
Any event 1 (<1%) 2 (<1%) 
Atrial fibrillation 0 1 (<1%) 
Atrial flutter 0 1 (<1%) 
Cardiac failure congestive 1 (<1%) 0 
Coronary artery disease 0 1 (<1%) 
      
Immune system disorders     
Any event 1 (<1%) 2 (<1%) 
Hypersensitivity 0 2 (<1%) 
Drug hypersensitivity 1 (<1%) 0 
      
Musculoskeletal and connective tissue disorders     
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System Organ Class 
Preferred Term 







Any event 2 (<1%) 1 (<1%) 
Myalgia 1 (<1%) 0 
Osteoarthritis 1 (<1%) 0 
Rotator cuff syndrome 0 1 (<1%) 
Tendon disorder 1 (<1%) 0 
      
Renal and urinary disorders     
Any event 1 (<1%) 2 (<1%) 
Renal cyst 1 (<1%) 0 
Renal failure 0 1 (<1%) 
Renal failure chronic 0 1 (<1%) 
      
General disorders and administration site conditions     
Any event 2 (<1%) 0 
Non-cardiac chest pain 1 (<1%) 0 
Pyrexia 1 (<1%) 0 
      
Pregnancy, puerperium and perinatal conditions     
Any event 0 2 (<1%) 
Abortion spontaneous 0 1 (<1%) 
Ectopic pregnancy 0 1 (<1%) 
      
Reproductive system and breast disorders     
Any event 2 (<1%) 0 
Bartholin's cyst 1 (<1%) 0 
Priapism 1 (<1%) 0 
      
Gastrointestinal disorders     
Any event 1 (<1%) 0 
Food poisoning 1 (<1%) 0 
      
Hepatobiliary disorders     
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System Organ Class 
Preferred Term 







Any event 0 1 (<1%) 
Cholelithiasis 0 1 (<1%) 
      
Metabolism and nutrition disorders     
Any event 1 (<1%) 0 
Type 2 diabetes mellitus 1 (<1%) 0 
      
Neoplasms benign, malignant and unspecified (incl cysts and 
polyps) 
    
Any event 0 1 (<1%) 
Ovarian cancer 0 1 (<1%) 
      
Skin and subcutaneous tissue disorders     
Any event 1 (<1%) 0 
Angioedema 1 (<1%) 0 
      
Vascular disorders     
Any event 0 1 (<1%) 
Deep vein thrombosis 0 1 (<1%) 
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Table S7. Viral Genotyping and Phenotyping Data. 
Subject Mutation Phenotype Treatment arm 
Integrase inhibitor resistance genotypic and phenotypic results at PDVF (n=7; each arm) 
None None None None 
NNRTI resistance genotypic and phenotypic results at PDVF (n=9) 
A K101E 1.9 FC to EFV EFV/TDF/FTC 
B K103K/N 14 FC to EFV EFV/TDF/FTC 
C K103N, G190G/A 22 FC to EFV EFV/TDF/FTC 
D G190G/A 20 FC to EFV EFV/TDF/FTC 
NRTI resistance genotypic and phenotypic results at PDVF (n=9) 
E 0 1.39 FC to DDI* DTG+ABC/3TC 
D K65K/R† No change EFV/TDF/FTC 
*DDI clinical cutoff = 1.30;  
†The Monogram Biosciences Net Assessment predicted resistance to ABC, DDI, FTC, 3TC, and TDF. 
 ABC denotes abacavir, DDI didanosine, DTG dolutegravir, EFV efavirenz, FC fold change, FTC 
emtricitabine, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse 




Figure S1. Graphical Representation of the Snapshot Algorithm. 
*Week X VL: last on-treatment (double-blind, if applicable) HIV-1 RNA VL in week X window. 
†Last VL: last on-treatment (double-blind, if applicable) HIV-1 RNA VL prior to week X. 
Subreasons: ‡discontinued due to AE or death; §discontinued for other reasons; ¶missing data 
but on-treatment. Note: In addition, changes in background antiretroviral therapy means 
virologic failure according to the Snapshot algorithm. However, no changes in antiretroviral 






Figure S2. Kaplan-Meier Plot of Time to Viral Suppression (Viral Load <50 copies/mL). 
The median time to viral suppression was 28 versus 84 days for DTG + ABC/3TC and 
EFV/TDF/FTC, respectively; the hazard ratio was estimated using Cox proportional hazard 
regression model. ABC denotes abacavir, DTG dolutegravir, EFV efavirenz, FTC emtricitabine, 
3TC lamivudine, QD once daily, and TDF tenofovir disoproxil fumarate.  
 
 
 
